Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02211131 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT02211131 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 150 participants.
The verdict
NCT02211131, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable stage IIIB, IIIC, or IVM1a melanoma.
Interventions
- DRUG Talimogene Laherparepvec
- PROCEDURE Immediate surgical resection of melanoma lesion(s)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2015-02-03 |
| Est. Completion | 2022-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02211131
The ClinicalTrials.gov registry entry for NCT02211131 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Talimogene Laherparepvec is the first listed.
NCT02211131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02211131 about?
NCT02211131 is a clinical study titled "Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma". This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable stage IIIB, IIIC, or IVM1a melanoma.
What is the current status of trial NCT02211131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2015-02-03. Estimated completion is 2022-04-28.
What interventions are being tested in trial NCT02211131?
The interventions under investigation include: Talimogene Laherparepvec (DRUG), Immediate surgical resection of melanoma lesion(s) (PROCEDURE).
Who is sponsoring clinical trial NCT02211131?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.